Organization Profile

You just read:

Data from a Phase 2 Study Presented at the 2012 ASCO Annual Meeting Continues to Show Early Activity of OGX-427 in Patients with Prostate Cancer

News provided by

OncoGenex Pharmaceuticals, Inc.

Jun 04, 2012, 08:01 ET